Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting episode artwork

EPISODE · Jul 22, 2026 · 1H 57M

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

from Hematologic Oncology Update

Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics:Introduction (0:00)Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lee (1:45)Current Utility of Antibody-Drug Conjugates for MM — Dr Lonial (33:55)Potential Role of Cereblon E3 Ligase Modulators in Therapy for MM — Dr Richardson (59:42)Chimeric Antigen Receptor T-Cell Therapy for R/R MM — Dr Alsina (1:30:24)CME information and select publications

Episode metadata supplied by the publisher feed · Published Jul 22, 2026

Embed this episode

NOW PLAYING

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

0:00 1:57:32

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Hematologic Oncology Update?

This episode is 1 hour and 57 minutes long.

When was this Hematologic Oncology Update episode published?

This episode was published on July 22, 2026.

Can I download this Hematologic Oncology Update episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!